ZBTB9 and cancer: These findings demonstrated that the abnormal expression of ZBTB9 in certain cancers could be caused via genetic alterations and promoter hypomethylation, which would contribute to the comprehensive cognition of LIHC tumorigenesis and guidance for potential treatment strategy.